UB Paderborn / Katalog / Suche / in CDI

Disentangling Dust Components in SN 2010jl: The First 1400 Days

The Astrophysical journal, 2020-05, Vol.894 (2), p.111

2020

Volltextzugriff (PDF)

The paradox-breaking panRAF plus SRC family kinase inhibitor, CCT3833, is effective in mutant KRAS-driven cancers

Annals of oncology, 2021-02, Vol.32 (2), p.269-278

2021

Volltextzugriff (PDF)

RAS Mutations in Cutaneous Squamous-Cell Carcinomas in Patients Treated with BRAF Inhibitors

The New England journal of medicine, 2012-01, Vol.366 (3), p.207-215

2012

Volltextzugriff (PDF)

The dust mass in Cassiopeia A from infrared and optical line flux differences

Monthly notices of the Royal Astronomical Society, 2021-06, Vol.504 (2), p.2133-2145

2021

Volltextzugriff (PDF)

Mechanism of Activation of the RAF-ERK Signaling Pathway by Oncogenic Mutations of B-RAF

Cell, 2004-03, Vol.116 (6), p.855-867

2004

Volltextzugriff (PDF)

B-RAF is a therapeutic target in melanoma

Oncogene, 2004-08, Vol.23 (37), p.6292-6298

2004

Volltextzugriff (PDF)

Nilotinib and MEK Inhibitors Induce Synthetic Lethality through Paradoxical Activation of RAF in Drug-Resistant Chronic Myeloid Leukemia

Cancer cell, 2011-12, Vol.20 (6), p.715-727

2011

Volltextzugriff (PDF)

Therapeutic efficacy of the paradox-breaking panRAF and SRC drug CCT3833/BAL3833 in KRAS-driven cancer models

European journal of cancer (1990), 2016-07, Vol.61, p.S199-S199

2016

Volltextzugriff (PDF)

Potent BRAF kinase inhibitors based on 2,4,5-trisubstituted imidazole with naphthyl and benzothiophene 4-substituents

Bioorganic & medicinal chemistry, 2013-03, Vol.21 (5), p.1284-1304

2013

Volltextzugriff (PDF)

Primary melanoma of the CNS in children is driven by congenital expression of oncogenic NRAS in melanocytes

Cancer discovery, 2013-04, Vol.3 (4), p.458-469

2013

Volltextzugriff (PDF)

862 - Therapeutic efficacy of the paradox-breaking panRAF and SRC drug CCT3833/BAL3833 in KRAS-driven cancer models

European journal of cancer (1990), 2016-07, Vol.61, p.S199-S199

2016

Volltextzugriff (PDF)

Novel Hinge Binder Improves Activity and Pharmacokinetic Properties of BRAF Inhibitors

Journal of medicinal chemistry, 2010-08, Vol.53 (15), p.5639-5655

2010

Volltextzugriff (PDF)

Novel Potent BRAF Inhibitors: Toward 1 nM Compounds through Optimization of the Central Phenyl Ring

Journal of medicinal chemistry, 2009-07, Vol.52 (13), p.3881-3891

2009

Volltextzugriff (PDF)

Development of an outpatient finger-prick glomerular filtration rate procedure suitable for epidemiological studies

Kidney international, 2006-04, Vol.69 (7), p.1272-1275

2006

Volltextzugriff (PDF)

Pyridoimidazolones as Novel Potent Inhibitors of v-Raf Murine Sarcoma Viral Oncogene Homologue B1 (BRAF)

Journal of medicinal chemistry, 2009-04, Vol.52 (8), p.2255-2264

2009

Volltextzugriff (PDF)

Development of Novel, Highly Potent Inhibitors of V-RAF Murine Sarcoma Viral Oncogene Homologue B1 (BRAF): Increasing Cellular Potency through Optimization of a Distal Heteroaromatic Group

Journal of medicinal chemistry, 2010-04, Vol.53 (7), p.2741-2756

2010

Volltextzugriff (PDF)

Novel tricyclic pyrazole BRAF inhibitors with imidazole or furan central scaffolds

Bioorganic & medicinal chemistry, 2010-09, Vol.18 (18), p.6934-6952

2010

Volltextzugriff (PDF)

BRAF Inhibitors Based on an Imidazo[4,5]pyridin-2-one Scaffold and a Meta Substituted Middle Ring

Journal of medicinal chemistry, 2010-03, Vol.53 (5), p.1964-1978

2010

Volltextzugriff (PDF)

Three new prodrugs for suicide gene therapy using carboxypeptidase G2 elicit bystander efficacy in two xenograft models

Cancer research (Chicago, Ill.), 2002-03, Vol.62 (6), p.1724-1729

2002

Volltextzugriff (PDF)

Dust masses for a large sample of core-collapse supernovae from optical emission line asymmetries: dust formation on 30-year time-scales

Monthly notices of the Royal Astronomical Society, 2022-08, Vol.515 (3), p.4302-4343

2022

Volltextzugriff (PDF)

2‑Aminomethylene-5-sulfonylthiazole Inhibitors of Lysyl Oxidase (LOX) and LOXL2 Show Significant Efficacy in Delaying Tumor Growth

Journal of medicinal chemistry, 2020-03, Vol.63 (5), p.2308-2324

2020

Volltextzugriff (PDF)

SN 2018hfm: a low-energy Type II supernova with prominent signatures of circumstellar interaction and dust formation

Monthly notices of the Royal Astronomical Society, 2022-01, Vol.509 (2), p.2013-2032

2022

Volltextzugriff (PDF)

Serendipitous detection of the dusty Type IIL SN 1980K with JWST/MIRI

Monthly notices of the Royal Astronomical Society, 2024-02, Vol.529 (1), p.155-168

2024

Volltextzugriff (PDF)

Toward the Scale-Up of a Bicyclic Homopiperazine via Schmidt Rearrangement and Photochemical Oxaziridine Rearrangement in Continuous-Flow

Organic process research & development, 2021-01, Vol.25 (1), p.148-156

2021

Volltextzugriff (PDF)

Menü

Weitere Dienste

Einstellungen

Disentangling Dust Components in SN 2010jl: The First 1400 Days

The paradox-breaking panRAF plus SRC family kinase inhibitor, CCT3833, is effective in mutant KRAS-driven cancers

RAS Mutations in Cutaneous Squamous-Cell Carcinomas in Patients Treated with BRAF Inhibitors

The dust mass in Cassiopeia A from infrared and optical line flux differences

Mechanism of Activation of the RAF-ERK Signaling Pathway by Oncogenic Mutations of B-RAF

B-RAF is a therapeutic target in melanoma

Nilotinib and MEK Inhibitors Induce Synthetic Lethality through Paradoxical Activation of RAF in Drug-Resistant Chronic Myeloid Leukemia

Therapeutic efficacy of the paradox-breaking panRAF and SRC drug CCT3833/BAL3833 in KRAS-driven cancer models

Potent BRAF kinase inhibitors based on 2,4,5-trisubstituted imidazole with naphthyl and benzothiophene 4-substituents

Primary melanoma of the CNS in children is driven by congenital expression of oncogenic NRAS in melanocytes

862 - Therapeutic efficacy of the paradox-breaking panRAF and SRC drug CCT3833/BAL3833 in KRAS-driven cancer models

Novel Hinge Binder Improves Activity and Pharmacokinetic Properties of BRAF Inhibitors

Novel Potent BRAF Inhibitors: Toward 1 nM Compounds through Optimization of the Central Phenyl Ring

Development of an outpatient finger-prick glomerular filtration rate procedure suitable for epidemiological studies

Pyridoimidazolones as Novel Potent Inhibitors of v-Raf Murine Sarcoma Viral Oncogene Homologue B1 (BRAF)

Development of Novel, Highly Potent Inhibitors of V-RAF Murine Sarcoma Viral Oncogene Homologue B1 (BRAF): Increasing Cellular Potency through Optimization of a Distal Heteroaromatic Group

Novel tricyclic pyrazole BRAF inhibitors with imidazole or furan central scaffolds

BRAF Inhibitors Based on an Imidazo[4,5]pyridin-2-one Scaffold and a Meta Substituted Middle Ring

Three new prodrugs for suicide gene therapy using carboxypeptidase G2 elicit bystander efficacy in two xenograft models

Dust masses for a large sample of core-collapse supernovae from optical emission line asymmetries: dust formation on 30-year time-scales

Paradox-Breaking RAF Inhibitors that Also Target SRC Are Effective in Drug-Resistant BRAF Mutant Melanoma

2‑Aminomethylene-5-sulfonylthiazole Inhibitors of Lysyl Oxidase (LOX) and LOXL2 Show Significant Efficacy in Delaying Tumor Growth

SN 2018hfm: a low-energy Type II supernova with prominent signatures of circumstellar interaction and dust formation

Serendipitous detection of the dusty Type IIL SN 1980K with JWST/MIRI

Toward the Scale-Up of a Bicyclic Homopiperazine via Schmidt Rearrangement and Photochemical Oxaziridine Rearrangement in Continuous-Flow

Suchergebnisse filtern